Literature DB >> 6152129

Antiviral activity of Norakin (triperiden) and related anticholinergic antiparkinsonism drugs.

H W Presber, C Schroeder, B Hegenscheid, H Heider, J Reefschläger, H A Rosenthal.   

Abstract

In view of the coincidence of antiviral and antiparkinsonism activities of amantadine four antiparkinsonism drugs, NorakinR (triperiden), ParkopanR (trihexyphenidyl), AntiparkinR (diethylbenzhydramine) and AkinetonR (biperiden) were tested for antiviral activity in various virus-cell systems. Norakin inhibited the replication of influenza A viruses in chick embryo fibroblast, MDCK and Ehrlich ascites tumour cells. It also inhibited the replication of measles virus in Vero cells, 50% inhibitory concentrations being 2-6 micrograms/ml. The drugs were also active against influenza B virus. Several representatives of other virus families, e.g. vaccinia, vesicular stomatitis, polio type 1 and herpes simplex type 1 viruses were insensitive to the compounds.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6152129

Source DB:  PubMed          Journal:  Acta Virol        ISSN: 0001-723X            Impact factor:   1.162


  5 in total

1.  Neutral red-labeled influenza virus loses photosensitivity during absorption to host cells but not to erythrocytes.

Authors:  C Schroeder; H Heider; H J Eggers
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

2.  Mutations in the hemagglutinin gene associated with influenza virus resistance to norakin.

Authors:  S Prösch; H Heider; C Schroeder; D H Krüger
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

3.  The influence of Norakin on the reproduction of influenza A and B viruses.

Authors:  H Heider; S Markushin; C Schroeder; Y Ghendon
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

Review 4.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-12

Review 5.  Progress of small molecular inhibitors in the development of anti-influenza virus agents.

Authors:  Xiaoai Wu; Xiuli Wu; Qizheng Sun; Chunhui Zhang; Shengyong Yang; Lin Li; Zhiyun Jia
Journal:  Theranostics       Date:  2017-02-08       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.